Compare Novo Nordisk A/S (NVO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Palantir Technologies Inc — how do they compare? Novo Nordisk A/S trades at $38.44 (market cap $165.31B), while Palantir Technologies Inc trades at $202.39 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 2.9× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Palantir Technologies Inc for 78 Days on average.
| NVO | PLTR | |
|---|---|---|
Market Cap | $165.31B | $477.68B |
Volume | 11,432,838 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $63.98 | $207.18 |
52-Week Low | $35.29 | $107.27 |
Typical Hold Time | 116 Days | 78 Days |
Enterprise Value | $179.56B | $468.48B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Palantir (PLTR) trades at $194.04, up 1.02% today, near its recent high and above the consensus price target of $191.69. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company reported robust revenue of $4.48 billion in 2025, with net income surging to $1.63 billion and a net margin of 36.3%, while recent quarters have consistently beaten EPS expectations.
Outlook remains positive driven by AI platform growth and expanding commercial customer base, but high valuation ratios (P/E of 169.9, P/S of 83.02) pose risks. Investor sentiment is buoyed by analyst buy ratings (53.84%) and partnerships like the recent Armada alliance, though competitive pressures and execution challenges are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
